PROLIA® TREATMENT PLANNER
Prolia® treatment is associated with continuous increases in BMD and sustained low incidence of vertebral, non-vertebral and hip fractures for up to 10 years of therapy.1
The Prolia® BMD calculator and treatment planner provides information on treatment targets for postmenopausal women at risk of fracture. The tool is based on 10 years of data from patients treated with Prolia®.
Click below to find out how long, on average, you should treat your patients with Prolia® to achieve a certain increase in BMD.
The optimal total duration of anti-resorptive treatment for osteoporosis (including Prolia® and bisphosphonates) has not been established. The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of Prolia® on an individual patient basis, particularly after 5 or more years of use.2
BMD: bone mineral density.
- Bone HG, et al. Lancet Diabetes Endocrinol. 2017;5:513–23.
- Prolia® (denosumab) Summary of Product Characteristics. Amgen. Last revised February 2020.